Initially, the effects of different doses of ITF2357 were evaluated on melanoma cell viability by MTT assay in comparison with the well-known HDAC inhibitor suberoylanilide hydroxamic acid (SAHA, vorinostat). The gene discussed is HDAC9; the disease is melanoma.